Lidocain-Egis

Lidocaine Hydrochloride, the active ingredient in Lidocain-Egis, is a local anesthetic (amide) presented as an injection solution for intravenous use. It provides rapid onset of nerve block for minor surgical or diagnostic procedures and is also employed in the management of certain ventricular arrhythmias.

GNH USA supplies Lidocain-Egis as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to EU GMP standards and provides regulatory documentation for cross‑border procurement. This ensures product integrity and timely delivery to end‑users.

Lidocain-Egis, a local anesthetic acting on voltage‑gated sodium channels, is indicated for the following clinical situations:

- Minor surgical procedures: provides rapid, reversible loss of sensation to facilitate pain‑free operation. - Diagnostic procedures: enables comfortable performance of endoscopic or catheter‑based examinations. - Ventricular arrhythmias: stabilizes cardiac electrical activity to suppress life‑threatening rhythm disturbances.

Lidocain-Egis may be associated with adverse reactions that vary in frequency and severity.

Common Side Effects: - Tingling or numbness at the injection site. - Transient dizziness or light‑headedness. - Mild hypotension.

Serious or Rare Side Effects: - Anaphylaxis with rash, bronchospasm or angioedema. - Cardiac conduction disturbances such as bradycardia or heart block. - Central nervous system toxicity, including seizures.

When using Lidocain-Egis, clinicians should observe specific precautions to minimize risk.

- Patient assessment: evaluate cardiac history and existing conduction abnormalities before administration. - Dose titration: adjust dosage based on age, weight and hepatic function, especially in elderly patients. - Monitoring: continuously monitor ECG and blood pressure during intravenous infusion. - Drug interactions: avoid concurrent use with other class I anti‑arrhythmics or potent CYP450 inhibitors without supervision. - Allergic history: confirm no prior hypersensitivity to amide‑type local anesthetics. - Store at ambient temperature: keep the solution below 25 °C, protect from light, and retain in original packaging.

Lidocain-Egis can interact with several medicines that affect its plasma levels or cardiac effects.

Major Interactions (Avoid): - Class I anti‑arrhythmic agents (e.g., quinidine, procainamide) – additive cardiotoxicity. - Beta‑blockers (e.g., propranolol) – enhanced bradycardia and hypotension. - CYP3A4 inhibitors (e.g., ketoconazole) – increased lidocaine concentrations.

Moderate Interactions (Monitor Closely): - CYP1A2 inducers (e.g., carbamazepine) – reduced efficacy. - Diuretics (e.g., furosemide) – may potentiate hypotensive effects. - General anesthetics (e.g., propofol) – may require dosage adjustment.